Pasar al contenido principal

NUEVAS TERAPIAS PARA EL TRATAMIENTO DEL HEPATOCARCINOMA BASADAS EN FUNCIONES NO CONVENCIONALES DE LOS LNCRNAS EN LA RESPUESTA AL DAÑO DEL DNA Y LA TRADUCCION POLICISTRONICA

PID2021-128791OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA INVESTIGACION MEDICA APLICADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort

  • Camarena, Marta E.
  • Theunissen, Patrick
  • Ruiz, Marta
  • Ruiz Orera, Jorge, 1988-
  • Calvo Serra, Beatriz
  • Castelo Valdueza, Robert
  • Castro Alejos, Carla
  • Sarobe, Pablo
  • Fortes, Puri
  • Perera Bel, Júlia
  • Albà Soler, Mar
The expression of tumor-specific antigens during cancer progression can trigger an immune response against the tumor. Here, we investigate if microproteins encoded by noncanonical open reading frames (ncORFs) are a relevant source of tumor-specific antigens. We analyze RNA sequencing data from 117 hepatocellular carcinoma (HCC) tumors and matched healthy tissue together with ribosome profiling and immunopeptidomics data. Combining human leukocyte antigen-epitope binding predictions and experimental validation experiments, we conclude that around 40% of the tumor-specific antigens in HCC are likely to be derived from ncORFs, including two peptides that can trigger an immune response in humanized mice. We identify a subset of 33 tumor-specific long noncoding RNAs expressing novel cancer antigens shared by more than 10% of the HCC samples analyzed, which, when combined, cover a large proportion of the patients. The results of the study open avenues for extending the range of anticancer vaccines., This work was supported by the following grants and agencies: research projects PID2019-105595GB, PID2021-122726NB-I00, and PID2021-128791OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe” by the “European Union”; PI19/00004, PI20/00260, and PI22/00171, funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union and FEDER; 0011-1383-2019-000006 and 0011-1411-2021-000070, funded by Gobierno de Navarra; RTI2018-101759-B-I00 and the Instituto de Salud Carlos III, which finances Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd) and Red Española de Terapias Avanzadas TERAV ISCIII [RICORS: (RD21/0017), financed by the EU (NextGenerationEU, Plan de Recuperación Transformación y Resiliencia)]; AECC IDEAS20169FORT by Scientific Foundation of the Spanish Association Against Cancer; 2021SGR00042 by Generalitat de Catalunya; Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021; and European Reseach Council Advanced Grant NovoGenePop 101052538. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

APLF and long non-coding RNA NIHCOLE promote stable DNA synapsis in non-homologous end joining

  • Bragança, Sara de
  • Aicart-Ramos, Clara
  • Arribas-Bosacoma, Raquel
  • Rivera-Calzada, Ángel
  • Unfried, Juan P.
  • Prats-Mari, Laura
  • Marin-Baquero, Mikel
  • Fortes, Puri
  • Llorca, Óscar
  • Moreno-Herrero, Fernando
The synapsis of DNA ends is a critical step for the repair of double-strand breaks by non-homologous end joining (NHEJ). This is performed by a multicomponent protein complex assembled around Ku70-Ku80 heterodimers and regulated by accessory factors, including long non-coding RNAs, through poorly understood mechanisms. Here, we use magnetic tweezers to investigate the contributions of core NHEJ proteins and APLF and lncRNA NIHCOLE to DNA synapsis. APLF stabilizes DNA end bridging and, together with Ku70-Ku80, establishes a minimal complex that supports DNA synapsis for several minutes under piconewton forces. We find the C-terminal acidic region of APLF to be critical for bridging. NIHCOLE increases the dwell time of the synapses by Ku70-Ku80 and APLF. This effect is further enhanced by a small and structured RNA domain within NIHCOLE. We propose a model where Ku70-Ku80 can simultaneously bind DNA, APLF, and structured RNAs to promote the stable joining of DNA ends., This work was funded by grants PID2020-114429RB-I00 to O.L., PID2020-112998GB-I00 (open access) to F.M.-H., RTI2018-101759-B-I00 to P.F., and PID2021-1287910B-I00 to P.F., funded by Ministerio de Ciencia e Innovación (MICINN)/Agencia Estatal de Investigación (AEI/10.13039/501100011 033)_FEDER, EU, and co-funded by the European Regional Development Fund (ERDF); grants Y2018/BIO4747 and P2018/NMT4443 to both O.L. and F.M.-H., funded by the Autonomous Region of Madrid and co-funded by the European Social Fund (ESF) and the ERDF; grant EUREXCEL ref. 951214 to F. M.-H., funded by the CSIC; grant AECC IDEAS20169FORT to P.F., funded by the Scientific Foundation of the Spanish Association Against Cancer, and by the Instituto de Salud Carlos III (ISCIII), which supports CNIO, CIBEREhd, and TERAV ISCIII, funded by the European Union – NextGenerationEU, Plan de recuperación Transformación y Resiliencia. J.P.U. is a recipient of the Azrieli Foundation International Postdoctoral Fellowship, the Excellence Fellowship Program for International Postdoctoral from Israel CHE/IASH, and an EMBO Postdoctoral Fellowship. L.P.M. is a recipient of a PFIS fellowship (FI20/00074) by the ISCIII and ESF “Investing in Your Future”. M.M.-B. acknowledges support from MICINN as a recipient of an FPI fellowship (PRE2018-083464)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort

  • Camarena, Marta E.
  • Theunissen, Patrick
  • Ruiz, Marta
  • Ruiz Orera, Jorge, 1988-
  • Calvo Serra, Beatriz
  • Castelo Valdueza, Robert
  • Castro Alejos, Carla
  • Sarobe, Pablo
  • Fortes, Puri
  • Perera Bel, Júlia
  • Albà Soler, Mar
The expression of tumor-specific antigens during cancer progression can trigger an immune response against the tumor. Here, we investigate if microproteins encoded by noncanonical open reading frames (ncORFs) are a relevant source of tumor-specific antigens. We analyze RNA sequencing data from 117 hepatocellular carcinoma (HCC) tumors and matched healthy tissue together with ribosome profiling and immunopeptidomics data. Combining human leukocyte antigen-epitope binding predictions and experimental validation experiments, we conclude that around 40% of the tumor-specific antigens in HCC are likely to be derived from ncORFs, including two peptides that can trigger an immune response in humanized mice. We identify a subset of 33 tumor-specific long noncoding RNAs expressing novel cancer antigens shared by more than 10% of the HCC samples analyzed, which, when combined, cover a large proportion of the patients. The results of the study open avenues for extending the range of anticancer vaccines., This work was supported by the following grants and agencies: research projects PID2019-105595GB, PID2021-122726NB-I00, and PID2021-128791OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF: A way of making Europe” by the “European Union”; PI19/00004, PI20/00260, and PI22/00171, funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union and FEDER; 0011-1383-2019-000006 and 0011-1411-2021-000070, funded by Gobierno de Navarra; RTI2018-101759-B-I00 and the Instituto de Salud Carlos III, which finances Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREhd) and Red Española de Terapias Avanzadas TERAV ISCIII [RICORS: (RD21/0017), financed by the EU (NextGenerationEU, Plan de Recuperación Transformación y Resiliencia)]; AECC IDEAS20169FORT by Scientific Foundation of the Spanish Association Against Cancer; 2021SGR00042 by Generalitat de Catalunya; Ayudas Fundación BBVA a Proyectos de Investigación Científica en Biomedicina 2021; and European Reseach Council Advanced Grant NovoGenePop 101052538. Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them.